Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Deals Business Strategies Artificial Intelligence

Biopharma Investing In Better Success Rates Via AI, Data And New Modalities

  • Analysis

Executive Summary

Biopharma executives and investors gathered in San Diego on Feb. 28 and March 1 to talk about finding and funding innovation with a focus on novel technology and artificial intelligence that can improve drug discovery and development success rates.
Table

View full table

Advertisement

Related Content

Scrip
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
Scrip
Preparing Emerging Biotechs For The Best Deals – Insider Insights
Scrip
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Scrip
Amazon-Express Scripts Partnership? PBM Sees Opportunity In Uninsured Market
Scrip
Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection
Scrip
GSK And Google To Invest £540m In UK-Headquartered Bioelectronics JV
Scrip
Bayer And CRISPR Form Cutting Edge Gene Editing JV

Topics

Related Companies

Advertisement
Tags:
Deals Business Strategies Artificial Intelligence
UsernamePublicRestriction

Register

SC100492

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By